Consort Medical (CSRT) Trading Down 21.3% Following Analyst Downgrade
Consort Medical plc (LON:CSRT)’s share price was down 21.3% during trading on Tuesday after Shore Capital lowered their price target on the stock from GBX 1,255 to GBX 1,215. Shore Capital currently has a hold rating on the stock. Consort Medical traded as low as GBX 772 ($10.09) and last traded at GBX 772 ($10.09). Approximately 3,911 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 23,005 shares. The stock had previously closed at GBX 981 ($12.82).
Separately, Royal Bank of Canada raised shares of Consort Medical to an “outperform” rating and decreased their price objective for the company from GBX 1,430 ($18.69) to GBX 1,320 ($17.25) in a research report on Tuesday.
The firm also recently declared a dividend, which will be paid on Friday, February 15th. Investors of record on Thursday, January 17th will be issued a GBX 7.60 ($0.10) dividend. The ex-dividend date is Thursday, January 17th. This represents a yield of 0.99%.
About Consort Medical (LON:CSRT)
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.